Pentixapharm develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair.
Pentixapharm has raised $23.2M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2026.
Pentixapharm's investors include Eckert Life Science Accelerator.
Pentixapharm is headquartered in Würzburg, Germany.
Pentixapharm develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair.
Pentixapharm is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Pentixapharm — Funding & Investors." VCBacked, July 27, 2026, https://www.vcbacked.co/company/pentixapharm. Accessed August 2, 2026.
VCBacked. (2026). Pentixapharm — Funding & Investors. Retrieved August 2, 2026, from https://www.vcbacked.co/company/pentixapharm
{{cite web |title=Pentixapharm — Funding & Investors |url=https://www.vcbacked.co/company/pentixapharm |website=VCBacked |access-date=August 2, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated